 |
인쇄하기
취소
|
Novartis Korea, Handok holds symposium for Galvusmet
Novartis Korea and Handok Pharm said on February 20 that it has held a launching symposium for Galvusmet, a combination drug consisting of 850–1000 mg metformin and 50 mg of the DPP-4 inhibitor vildagliptin, while Galvus consists of 50 mg vildagliptin.
In treatment-naive patients, combinations of vildagliptin and both high-dose and low-dose metformin provide superior efficacy to monotherapy ...
In treatment-naive patients, combinations of vildagliptin and both high-dose and low-dose metformin provide superior efficacy to monotherapy ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.